MM treatment is associated with the development of Ab responses against DAPK2 and PIM1. (A) Plasma samples from 5 MM patients who demonstrated GVM responses (defined as clinical remission > 2 years) without GVHD were tested by ELISA. Three patients (Pt. 2, black bars; Pt. 3, gray bars; and Pt. 5, white bars) had new or markedly increased Ab reactivity to DAPK2 and/or PIM1 after HSCT. The dashed line indicates a cutoff based on 2 SD above the mean of Ab reactivity of 10 normal donors for each Ag. (B) Ab responses against DAPK2 (black bars) and PIM1 (gray bars) are also seen by ELISA in MM patients treated with standard chemotherapy or autologous HSCT, but are minimal in patients with untreated MM or healthy donors.